

Interaction of Rifampicin and Darunavir/Ritonavir or Darunavir/Cobicistat *In Vitro*

Owain Roberts, Saye Khoo, Andrew Owen, Marco Siccardi[†]

Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, 70
Pembroke Place, University of Liverpool, Liverpool, L69 3GF, UK

Running Title: Interaction of Rifampicin with Boosted Darunavir

[†]Author for correspondence and reprints:

Dr Marco Siccardi, Department of Molecular and Clinical Pharmacology, Institute of
Translational Medicine, University of Liverpool, 70 Pembroke Place, Liverpool, L69 3GF, UK

Tel: +44 (0) 151 794 8211

Fax: + 44 (0) 151 794 5656

E-mail: siccardi@liverpool.ac.uk

ABSTRACT

Treatment of HIV patients co-infected with tuberculosis (TB) is challenging due to drug-drug interactions (DDIs) between antiretrovirals (ARVs) and anti-TB drugs. The aim of this study was to quantify the effects of cobicistat (COBI), or ritonavir (RTV), in modulating DDIs between darunavir (DRV) and rifampicin (RIF) in a human hepatocyte-based *in vitro* model. Human primary hepatocyte cultures were incubated with RIF alone, or in combination with either COBI or RTV for three days, followed by co-incubation with DRV for one hour. Resultant DRV concentrations were quantified by HPLC-UV, and the apparent intrinsic clearance ($CL_{int,app}$) of DRV was calculated. Both RTV and COBI lowered RIF-induced increases in $CL_{int,app}$ in a concentration-dependent manner. Linear regression analysis showed that \log_{10} RTV and \log_{10} COBI concentrations were associated with percentage inhibition of RIF-induced elevations in DRV $CL_{int,app}$. $\beta = -94$ (95% CI = -108 to -80; $P=0.0001$), and $\beta = -61$ (95% CI = -73 to -49; $P=0.0001$), respectively. RTV was more effective in lowering 10 μ M RIF-induced elevations in DRV $CL_{int,app}$ ($EC_{50} = 1.54 \mu$ M) than COBI ($EC_{50} = 2.58 \mu$ M). Incubation of either RTV, or COBI, in combination with RIF was sufficient to overcome RIF-induced elevations in DRV $CL_{int,app}$, with RTV more potent than COBI. These data provide the first *in vitro* experimental insight into DDIs between RIF and COBI-boosted or RTV-boosted DRV, and will be useful to inform physiologically-based pharmacokinetic models to aid in optimising dosing regimens for the treatment of HIV-TB patients receiving concomitant ARVs and anti-TB drugs.

INTRODUCTION

Approximately 25% of human immunodeficiency virus-1 (HIV)-infected patients worldwide are co-infected with *Mycobacterium tuberculosis* (1, 2), accounting for 390,000 deaths in 2014 (3). Clinical management of HIV-tuberculosis (HIV-TB) patients presents significant challenges, especially in resource-limited settings (2, 4), where virological failure or intolerance to first-line antiretroviral therapy requires the use of HIV protease inhibitors (PIs) (5). PIs largely undergo phase I metabolism by cytochrome p450 3A4 (CYP3A4), and are also substrates of P-glycoprotein (P-gp; ABCB1) (6). Consequently, PIs are commonly administered in combination with pharmacokinetic (PK) “boosters” such as ritonavir (RTV) or cobicistat (COBI), which act by inhibiting CYP3A4-mediated PI metabolism and P-gp-mediated PI efflux, thereby improving the PK profile of PIs by prolonging PI half-life, and increasing PI bioavailability (7-9).

Rifampicin (RIF) is an essential component of short-course anti-TB treatment regimens (2, 10); however, RIF is also a potent inducer of the expression and activity of several metabolic enzymes – including CYP3A4 (11). Co-administering RIF with PIs can result in clinically-significant drug-drug interactions (DDIs), whereby PI bioavailability may be significantly reduced (>75%) (10, 12-14). Consequently, administering standard-doses of RTV-boosted PIs to HIV-TB patients receiving RIF is contraindicated under the current World Health Organisation (WHO) guidelines (15). The search for effective second-line therapeutic options for the treatment of HIV-TB co-infected patients is therefore a research priority (16).

Darunavir (DRV) is chiefly metabolised by CYP3A4 (17) and co-administration of a low-dose of either RTV or COBI together with DRV increases DRV systemic bioavailability

(18, 19). In addition, the high barrier to genetic resistance, as well as the tolerability, safety profile, and potency of DRV - when administered in combination with a low-dose of either RTV (DRV/r), or COBI (DRV/c) - have made these fixed-dose combinations important options for the treatment of HIV-patients (20-22).

Previous studies have demonstrated markedly reduced exposure of RTV-boosted PIs, including atazanavir (ATV) (12), indinavir (IDV) (13), and lopinavir (LPV) (14), as well as an increased risk of hepatotoxicity when RIF is co-administered with these drugs in healthy volunteers. For this reason, studies aimed at investigating DDIs between DRV/r and RIF in HIV-negative subjects have not been undertaken. Similarly, the extent of the DDI between DRV/c and RIF remains unknown. A recent population PK (pop-PK) analysis showed that it was possible to offset the effects of RIF on DRV C_{trough} by increasing the dose of DRV/r administered (23); raising the possibility that RTV may overcome potential DDIs between DRV and RIF *in vitro* and *in vivo*. The aim of the present study was to quantify - using an *in vitro* model - the extent of DDIs arising from co-incubation of RIF with either RTV or COBI, by specifically measuring the apparent intrinsic clearance ($CL_{int.app.}$) of DRV by primary human hepatocytes.

MATERIALS AND METHODS

Chemicals. DRV (Cat. No.: S1620) and COBI (Cat. No.: S2900) were purchased from Selleckchem (Munich, Germany). RIF (Cat. No.: R3501), RTV (Cat. No.: SML0491), potassium phosphate monobasic (Cat. No.: P0662), Hanks' balanced salt solution (Cat. No.: H8264), methanol (Cat. No.: 34860), and acetonitrile (Cat. No.: 34967) were purchased from Sigma-Aldrich (Poole, UK). Orthophosphoric acid (Cat. No.: 153154D) was purchased from VWR (Lutterworth, UK). HPLC-grade water was produced by an ELGA PureLab system (Veolia Water Technologies, High Wycombe, UK).

Primary Hepatocytes. Cryopreserved primary human hepatocytes were purchased from Life Technologies (Cat. No.: HMCPI5; Inchinnan, Scotland). Hepatocytes from a total of four donors were used (**Table 1**).

Stock Solutions. Stock solutions of COBI, DRV, RIF and RTV were freshly prepared in 100% (v/v) methanol at concentrations 6443, 1684.3, 15000 and 6935.4 μM respectively. Prior to use in experiments, all stock solutions were sterile-filtered through a Millex 0.22 μm polyethersulfone membrane (Millipore, Cat. No.: SLGP033RS; Watford, UK), and were either used immediately, or were stored at $-20\text{ }^{\circ}\text{C}$ for up to five days prior to use.

Concentrations of drugs used in this study. Primary cryopreserved human hepatocytes were treated with a range of concentrations of test compounds - COBI (0.13—12.76 μM), RIF (0.50—20.00 μM) and RTV (0.01—10.00 μM) - spanning the therapeutic plasma concentration range in humans as determined from clinical PK data (24), (25). The concentration of DRV used in

experiments (5 μ M), was selected from a value within the therapeutic range of DRV, as obtained from clinical PK data (18).

Culture of Primary Human Hepatocytes. Primary cryopreserved human hepatocytes were thawed in Cryopreserved Hepatocyte Recovery Medium (CHRM[®], Life Technologies, Cat. No.: CM7000) and were re-suspended in Williams' Medium E (WME) plating medium (WME Life Technologies, Cat. No.: A1217601, supplemented with Hepatocyte Plating Supplement Pack, Life Technologies, Cat. No.: CM3000). Cell viability was determined using a NucleoCounter[®] NC-100[™] (Sartorius Ltd., Epsom, UK). Viable cells were plated on collagen-coated 96-well cell culture plates (Life Technologies, Cat. No.: CM1096) at a density of 6.5×10^4 cells per well in 110 μ l of WME plating medium. Hepatocytes were incubated in a humidified incubator at 37 °C containing 5% (v/v) CO₂ for five hours prior to removal of the WME plating medium, and overlaying the hepatocyte monolayer with 70 μ l per well of Geltrex[™] LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Life Technologies, Cat. No.: A1413202) diluted in WME incubation medium (WME Life Technologies, Cat. No.: A1217601, supplemented with Hepatocyte Maintenance Supplement Pack, Life Technologies, Cat. No.: CM4000) to a final concentration of 0.35 mg/ml. Cells were then incubated in a humidified incubator at 37 °C containing 5% (v/v) CO₂ for 24 hours, prior to removal of the WME incubation medium and replacement with 110 μ l of fresh WME incubation medium containing test compounds: COBI (0.128—12.76 μ M), RTV (0.01—10 μ M), RIF (0.5—20 μ M) or methanol (0.3% v/v; vehicle control). At 24 hours, and 48 hours post-initial treatment, WME incubation medium was removed, and replaced with fresh WME incubation medium containing test compounds. At 72

hours post-initial treatment cells were treated with test compounds together with DRV (5 μ M) for 60 minutes.

Quantification of Darunavir by HPLC-UV. Following 60 minutes of incubation of hepatocytes with test compounds together with 5 μ M DRV, 100 μ l of WME incubation medium was removed from each well and was transferred to Corning[®] Pyrex[®] 75 x 12 mm borosilicate glass tubes (Appleton-Woods, Cat. No.: KC350) containing 300 μ l of 100% acetonitrile. Standards and quality control samples were prepared in WME incubation medium and were treated in the same way. All samples were then vortexed for five seconds, and were dried in a Jouan RC10.22 vacuum centrifuge for six hours at room temperature (18—25°C). After drying, samples were re-constituted in 330 μ l of 20% (v/v) acetonitrile and 80% (v/v) H₂O. One hundred microlitres of the resultant suspension was used to quantify DRV by HPLC-UV.

Chromatographic separation of DRV was achieved using a Waters Atlantis T3 (4.6 x 100 mm, 3 μ m) column (Waters, Elstree, UK) equipped with a 10 x 4 mm, 3 μ m Fortis C18 Guard (Fortis[™] Technologies Ltd., Chester, UK). A Dionex P680 HPLC pump, Dionex ASI-100 automated sample injector and a Dionex UVD170U UV detector (Thermo Fisher Ltd., Hemel-Hempstead, UK) were used. Mobile phases C (25 mM KH₂PO₄, pH 3.3/orthophosphoric acid) and D (100% acetonitrile) were used in a step-gradient elution as follows: 70% C/30% D from 0.0 to 1.5 min, 35% C/65% D from 1.5 to 7.0 min, 20% C/80% D from 7.0 to 9.5 min and 70% C/30% D from 9.5 to 12.5 min. Elution was carried out at room temperature (18—25°C), and the flow rate was maintained at 1.00 ml/min. Chromatograms were analysed and DRV was quantified at 267 nm using Chromeleon software (version 6.8; Thermo Fisher Ltd.). Each experimental condition was assessed in triplicate. The lower limit of detection (LOQ) of DRV

was determined to be 0.156 μM . The assay was linear between 0.156 μM and 10 μM (upper LOQ). The mean coefficient of variability (CV) of intra-day precision was 2.6%, whilst the mean CV of intra-day accuracy was 2.0%. The mean CV of inter-day precision was 2.2%, and the mean CV of inter-day accuracy was 1.2%. The mean recovery of DRV from WEM was 96.1%.

Calculation of $\text{CL}_{\text{int.app}}$ of Darunavir in Hepatocytes. Apparent intrinsic clearance ($\text{CL}_{\text{int.app}}$) of DRV was calculated based on a method described previously (26). This is summarised in **Equation 1:**

Equation 1: $\text{CL}_{\text{int.app}} = (\ln 2 / \text{in vitro } t_{1/2}) \times (\mu\text{l incubation volume} / 10^6 \text{ hepatocytes})$

Results were expressed as the mean \pm SD ($\mu\text{l}/\text{min}/10^6$ hepatocytes) of a total of three donors per condition tested. Three biological replicates were quantified per condition tested, using hepatocytes obtained from three separate donors in each case.

Data and Statistical Analysis. Statistical analyses were carried out using IBM[®] SPSS[®] Statistics (Version 22; IBM Corporation, Armonk, NY, USA). All data were assessed for normality using a Shapiro–Wilk test. Univariate and stepwise-elimination multivariate linear regression analyses were conducted to characterise the influence of co-incubating primary human hepatocytes with various concentrations of RTV or COBI together with RIF on DRV $\text{CL}_{\text{int.app}}$. Effective concentration (EC_{50}) was calculated using GraphPad Prism[®] (Version 5; GraphPad Software, Inc. La Jolla, CA, USA).

RESULTS

Assessment of the $CL_{int.app.}$ of Darunavir Following Combination Incubation of Primary Human Cryopreserved Hepatocytes with Ritonavir and Rifampicin. Primary human hepatocytes are commonly used as a tool to predict hepatic metabolic clearance of xenobiotics and DDIs *in vitro* (27, 28). Using this model system, the $CL_{int.app.}$ of DRV was initially calculated under control conditions in which hepatocytes (Lot HU1399, Lot HU1587 and Lot HU1621) were incubated with DRV alone. Under these conditions, mean DRV $CL_{int.app.}$ was $10.5 \pm 3.8 \mu\text{l/min}/10^6$ hepatocytes ($n=3$). Incubation of hepatocytes with RIF was sufficient to markedly increase DRV $CL_{int.app.}$ at each concentration of RIF tested (0.5—20 μM) (**Fig. 1**). The maximal RIF-induced increase (1.9 ± 0.3 -fold; $n=3$) in DRV $CL_{int.app.}$ was observed with 10 μM RIF (**Fig. 1**).

Co-incubation of RIF with RTV reduced 10 μM RIF-induced increases in $CL_{int.app.}$ in a RTV concentration-dependent manner (**Fig. 1**). Notably, RTV (1 μM) was sufficient to overcome the effect of 10 μM RIF on DRV $CL_{int.app.}$, reducing DRV $CL_{int.app.}$ to 0.78 ± 0.25 -fold – equivalent to -22% when compared to control levels in which cells were treated with DRV alone ($n=3$; **Fig. 1**). Increasing RIF concentrations above 10 μM (12.5—20 μM) did not impact the effectiveness of RTV to overcome RIF-elevated DRV $CL_{int.app.}$ (**Fig. 1**). Specifically, 1 μM RTV lowered 12.5 μM RIF-induced and 20 μM RIF-induced DRV $CL_{int.app.}$ by 55% and 47%, to ($8.6 \pm 3.2 \mu\text{l/min}/10^6$ hepatocytes; $n=3$) and ($8.8 \pm 3.4 \mu\text{l/min}/10^6$ hepatocytes; $n=3$), respectively.

Assessment of the $CL_{int.app.}$ of Darunavir Following Combination Incubation of Primary Human Cryopreserved Hepatocytes with Cobicistat and Rifampicin. In a separate set of experiments, human hepatocytes from three individual donors (Lot HU1399, Lot HU1574 and Lot HU1587) were used to determine the effects of incubating rifampicin together with cobicistat on DRV $CL_{int.app.}$. Under control conditions, where primary human cryopreserved hepatocytes were incubated with DRV alone, DRV $CL_{int.app.}$ was $13.2 \pm 1.8 \mu\text{l/min}/10^6$ hepatocytes, ($n=3$). Incubation of hepatocytes with RIF (0.5—20 μM), induced a mean increase in DRV $CL_{int.app.}$ of 55.8%. In cells treated with 1 μM RIF, co-incubation with the lowest concentration of COBI tested (0.42 μM) was effective in lowering RIF-induced DRV $CL_{int.app.}$ by 36.9%, yielding a DRV $CL_{int.app.}$ of $12.2 \pm 2.8 \mu\text{l/min}/10^6$ hepatocytes ($n=3$). Hepatocytes treated with 10 μM RIF exhibited a DRV $CL_{int.app.}$ of $21.6 \pm 2.6 \mu\text{l/min}/10^6$ hepatocytes ($n=3$). COBI induced a concentration-dependent attenuation of the DRV $CL_{int.app.}$, elicited by 10 μM RIF, with 1.28 μM COBI being sufficient to lower DRV $CL_{int.app.}$ to $11.6 \pm 2.6 \mu\text{l/min}/10^6$ hepatocytes ($n=3$), 13% below DRV control levels (**Fig. 2**). COBI was also effective at reducing $CL_{int.app.}$ elevations induced by higher concentrations of RIF, as co-incubation with 1.28 μM COBI reduced 20 μM RIF-elevated DRV $CL_{int.app.}$ by 46% ($12.4 \pm 3.9 \mu\text{l/min}/10^6$ hepatocytes; $n=3$).

Comparison of Cobicistat- and Ritonavir-mediated Reduction of Rifampicin-Induced

Darunavir $CL_{int.app.}$. To compare the relative effectiveness of RTV and COBI to attenuate RIF-induced increases in DRV $CL_{int.app.}$, the percentage inhibition of 10 μ M RIF-induced elevations in DRV $CL_{int.app.}$ achieved by co-incubation with either COBI (0.13—12.76 μ M), or RTV (0.1—10 μ M), was determined in comparison to control conditions where cells were treated with 10 μ M RIF alone (**Fig. 3**). The effective concentration 50% of maximum response (EC_{50}) of COBI and RTV calculated from the percentage-change in DRV $CL_{int.app.}$ under these conditions was 1.5 μ M for COBI and 2.6 μ M for RTV (**Fig. 3**). In addition, the maximal inhibition of 10 μ M RIF-induced elevations achieved by COBI and RTV were different, with RTV resulting in a 69.5% inhibition of 10 μ M RIF-induced increases in DRV $CL_{int.app.}$, whilst COBI-mediated reduction in 10 μ M RIF-induced increases in DRV $CL_{int.app.}$ was 56.9% ($P=0.05$).

Following data normalisation, linear regression analysis of the effects of RTV and COBI in combination with RIF at each concentration tested on the percentage change in DRV $CL_{int.app.}$ showed an association between \log_{10} RTV concentrations, and \log_{10} COBI concentrations and percentage inhibition of RIF-induced DRV $CL_{int.app.}$ of $\beta = -94$ (95% CI = -108 to -80; $P=0.0001$), and $\beta = -61$ (95% CI = -73 to -49; $P=0.0001$), respectively. Conducting linear regression analysis of the effects of RIF on DRV $CL_{int.app.}$ revealed that RIF exerted a similar effect on DRV $CL_{int.app.}$ in the two independent sets of RTV and COBI experiments, with a positive association observed between RIF concentration and DRV $CL_{int.app.}$ of $\beta = 22$ (95% CI = 9 to 35; $P=0.001$) and $\beta = 16$ (95% CI = 5 to 27; $P=0.004$) in the RTV experiments, and COBI experiments, respectively.

DISCUSSION AND CONCLUSIONS

RIF strongly induces the expression of metabolic enzymes such as CYP3A4 (29-31), and can also induce the activity of drug transporters (32). Collectively, this can result in clinically-relevant DDIs in patients that receive RIF together with other medications (11, 33). These DDIs present challenges for the treatment of HIV-TB patients, as several therapeutic options are contraindicated due to known DDIs (10), whilst other potentially viable treatment regimens may either be delayed, or avoided completely due to hypothetical DDIs that are predicted to occur between anti-TB drugs and ARVs such as PIs. For example, co-administering the standard-dose of any PI with RIF is currently contraindicated under WHO guidelines (15), but the extent of potential DDIs between RIF and PIs has not been determined for all PIs, including DRV. Co-administering dose-adjusted LPV/r, or SQV/r together with RIF is indicated, albeit with the caveat that high levels of toxicity can occur. This raises the possibility that administering other PIs, such as RTV-, or COBI-boosted DRV, together with RIF may also be feasible. The present study addresses this issue by providing the first experimental insight into the effects of co-incubating either RTV, or COBI, together with RIF on DRV $CL_{int.app.}$ in a human hepatocyte-based *in vitro* model of drug metabolism.

Utilisation of human hepatocytes to predict hepatic metabolic clearance of xenobiotics is well-established (27, 28). In this study, incubation of cryopreserved human hepatocytes with RIF increased DRV $CL_{int.app.}$ (**Fig. 1** and **Fig. 2**). This is likely due to induction of CYP3A4 (17, 34), although the effects of RIF on transporters may also be important (28). Uptake transporters such as organic anion transporting polypeptide isoform 1B1 (OATP1B1) (35), and efflux transporters such as P-gp (36), have been shown to play a role in PI elimination, and therefore

may also be relevant in the DDIs between RIF and COBI-, or RTV-boosted DRV. Indeed, RIF has been shown to inhibit OATP1B1 (37), and DRV uptake by OATP1B1 and OATP1B3 in transfected CHO cells has been reported (38). Utilising a pop-PK-model, it has been suggested that OATP3A1 polymorphisms are associated with DRV PK (39), in addition, a recent physiologically-based PK (PBPK) modelling-based study that investigated the PK of DRV/r during pregnancy has also suggested a role for hepatic transporters in DRV disposition (40).

Co-incubation of human cryopreserved hepatocytes with COBI and RIF, or RTV and RIF - using concentrations spanning the *in vivo* therapeutic range of these compounds - revealed that both RTV and COBI could reduce RIF-enhanced DRV $CL_{int.app.}$ in a concentration-dependent manner (**Fig. 1** and **Fig. 2**). RTV was more effective than COBI at attenuating the RIF-induced increase in DRV $CL_{int.app.}$, with RTV exhibiting a lower EC_{50} compared to COBI, whilst RTV also achieved greater maximal inhibition of the 10 μ M RIF-induced increase in DRV $CL_{int.app.}$ compared to COBI (**Fig. 3**). Furthermore, regression analysis revealed a stronger effect of RTV in comparison to COBI for their relative contribution in reducing RIF-induced increases in DRV $CL_{int.app.}$. Due to the more recent approval of COBI, data regarding potential DDIs between COBI and other medications is more limited than with RTV. The expected differential DDI profiles of COBI and RTV when administered with co-medications have been recently reviewed (41, 42). RTV and COBI both serve as strong inhibitors of CYP3A4 *in vivo* (43, 44); however, RTV is also known to induce the expression of various metabolic enzymes, including CYP3A4, in primary human hepatocytes *in vitro* (30). Very few studies aimed at investigating the relative effects of COBI as an inducer of metabolic enzyme expression have thus far been conducted, although it has been suggested that the induction potential of COBI is less than that of RTV (45),

and that COBI is not expected to induce *CYP3A4* expression (46). It was recently suggested that hepatic uptake of RTV occurs chiefly by passive diffusion (47). In addition, RTV has been shown to induce expression of the efflux transporters *P-gp* (30), and multidrug resistance-associated protein 1 (*MRP1*; *ABCC1*) in primary human hepatocytes *in vitro* (30). DRV is a substrate of *P-gp* (48) and OATP1A2 and OATP1B1 (35), whilst RTV appears to inhibit *P-gp* (48), as well as OATP1B1 and OATP1B3 (38), *in vitro*. At the same time, RIF has been described as an inhibitor of various OATPs *in vitro*, including OATP1B1 and OATP1B3 (38). In addition, chronic exposure to RIF has been shown to exert an inhibitory effect on *P-gp* *in vitro* (49). It remains to be seen therefore what the net contribution of transporters such as OATP1B1, OATB1B3 and *P-gp* may be on plasma levels of DRV *in vivo*, especially when DRV is administered in combination with other compounds such as RIF.

The PK profiles of DRV/r (800/100 mg, *qd*) and DRV/c (800/150 mg, *qd*) in HIV-infected patients are broadly similar (50, 51). However, in a study conducted in healthy volunteers, it has been reported that DRV C_{\min} values were 30% lower in individuals treated with DRV/c compared with individuals treated with DRV/r (52). In addition, PK analysis of the PI tipranavir (TPV), when administered in combination with COBI or RTV in healthy volunteers, showed that TPV AUC, C_{\max} and C_{τ} levels were significantly lower with COBI compared to RTV (53). Collectively, these studies suggest that the pharmacoenhancement with COBI is not always equal to that of RTV.

Whilst no studies have been conducted investigating the effects of co-administering either DRV/r or DRV/c with RIF on DRV bioavailability, it has recently been shown using a pop-PK modelling approach that administering dose-adjusted DRV/r (1600/200 mg *qd*; 800/100

286 mg *bid*; or 1200/150 mg *bid*) can potentially overcome the effects of RIF on DRV C_{trough} , albeit
287 with the caveat that RTV-related side-effects may occur and that a higher pill burden would be
288 required (23). These *in silico* findings are in general agreement with the *in vitro* outcomes of
289 the present study. In addition, it is interesting to speculate that given the observation that low
290 concentrations of either RTV or COBI could overcome RIF-induced elevations in DRV $CL_{\text{int.app.}}$,
291 increasing the dose of the pharmacoenhancer may not be necessary to achieve therapeutic
292 concentrations of DRV in combination with RTV or COBI. Even so, extrapolating the *in vivo*
293 significance of *in vitro* data presents multiple challenges (54, 55), and it is difficult to directly
294 infer how these results may translate *in vivo*. For example, increasing the dose of RTV in
295 combination with a given PI is not always sufficient to overcome the effects of RIF. Indeed, a
296 study of the effects of RIF on the steady-state PK of ATV with RTV in healthy volunteers
297 showed that administering ATV/RTV 300/100 mg, ATV/RTV 300/200 mg, and ATV/RTV
298 400/200 mg was insufficient to completely overcome the inductive potential of RIF 600 mg (12).
299 In an effort to better understand the absorption, distribution, metabolism and elimination of
300 various compounds, the use of PBPK models has recently gained popularity (56). Various PBPK
301 models have been developed that have proven useful in predicting the effects of administering
302 ARVs in HIV patients with co-morbidities (57). Indeed, a recent study described the
303 development of a PBPK model for predicting clinical DDIs from RIF-based *in vitro* human
304 hepatocyte data (58), and it is therefore hoped that the data presented herein will be of use in the
305 development of PBPK models to predict the effects of co-administering boosted PIs with anti-TB
306 drugs.

In conclusion, the results presented herein provide insight into the relative effects of RTV and COBI as pharmacoenhancers of DRV in the presence of RIF in an *in vitro* model of drug metabolism, which can be used in conjunction with PBPK models to rationalise future strategies aimed at optimising treatment regimens. Further work should aim to elucidate the mechanisms that give rise to the differential inhibitory potential of COBI and RTV demonstrated herein, as well as to validate these results *in vivo*. Future studies should also aim to further evaluate the effects of COBI and RTV on gene expression, as well as the effects of these compounds on the expression and activity of various drug transporters *in vitro*. Finally, it would also be of interest to use this model system to evaluate potential DDIs that may occur between RIF and RTV, or COBI, in combination with other PIs, or with other co-medications.

318 **ACKNOWLEDGEMENTS**

319 This work was presented in part at Conference on Retroviruses and Opportunistic Infections
320 (CROI), Boston, Massachusetts, USA, 22—25 February 2016, (Poster Number 459). S. K. has
321 received research grants and/or travel bursaries from ViiV healthcare, Gilead Sciences, Janssen
322 Pharmaceutica NV and Merck. A.O. has received research grants and/or consultancy from
323 AstraZeneca, ViiV Healthcare, Merck and Janssen Pharmaceutica NV, and is a co-inventor on
324 patents relating to drug delivery of anti-infective drugs. M. S. has received research grants from
325 Janssen Pharmaceutica NV and ViiV.

326

327 **FUNDING INFORMATION**

328 This study was funded by Janssen, Pharmaceutical Companies of Johnson & Johnson. Grant
329 number JXR11327.

REFERENCES

1. **Kwan CK, Ernst JD.** 2011. HIV and tuberculosis: a deadly human syndemic. *Clinical microbiology reviews* **24**:351-376.
2. **Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R.** 2013. Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. *BMC medicine* **11**:253.
3. **WHO 2015.** World Health Organization Global Tuberculosis Report 2015, 20th Edition. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1, Geneva.
4. **Bruchfeld J, Correia-Neves M, Kallenius G.** 2015. Tuberculosis and HIV Coinfection. Cold Spring Harbor perspectives in medicine **5**.
5. **Hosseiniipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB.** 2013. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. *The Journal of infectious diseases* **207 Suppl 2**:S49-56.
6. **Sankatsing SU, Beijnen JH, Schinkel AH, Lange JM, Prins JM.** 2004. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. *Antimicrobial agents and chemotherapy* **48**:1073-1081.
7. **Josephson F.** 2010. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. *Journal of internal medicine* **268**:530-539.
8. **Zeldin RK, Petruschke RA.** 2004. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. *The Journal of antimicrobial chemotherapy* **53**:4-9.
9. **Larson KB, Wang K, Delille C, Otofokun I, Acosta EP.** 2014. Pharmacokinetic enhancers in HIV therapeutics. *Clinical pharmacokinetics* **53**:865-872.
10. **Regazzi M, Carvalho AC, Villani P, Matteelli A.** 2014. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. *Clinical pharmacokinetics* **53**:489-507.
11. **Baciewicz AM, Chrisman CR, Finch CK, Self TH.** 2013. Update on rifampin, rifabutin, and rifapentine drug interactions. *Current medical research and opinion* **29**:1-12.
12. **Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R.** 2006. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. *Antimicrobial agents and chemotherapy* **50**:3336-3342.
13. **Justesen US, Andersen AB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen C.** 2004. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **38**:426-429.
14. **la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, Koopmans PP, Hekster YA, Burger DM.** 2004. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. *Antimicrobial agents and chemotherapy* **48**:1553-1560.
15. **WHO 2013.** World Health Organization Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1. Geneva.
16. **Dooley KE, Kim PS, Williams SD, Hafner R.** 2012. TB and HIV Therapeutics: Pharmacology Research Priorities. *AIDS research and treatment* **2012**:874083.
17. **Rittweger M, Arasteh K.** 2007. Clinical pharmacokinetics of darunavir. *Clinical pharmacokinetics* **46**:739-756.

18. **Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A.** 2009. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. *Drug metabolism and disposition: the biological fate of chemicals* **37**:809-820.
19. **Kakuda TN, Van De Castele T, Petrovic R, Neujens M, Salih H, Opsomer M, Hoetelmans RM.** 2014. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. *Antiviral therapy* **19**:597-606.
20. **Deeks ED.** 2014. Darunavir: a review of its use in the management of HIV-1 infection. *Drugs* **74**:99-125.
21. **Capetti A, Cossu MV, Rizzardini G.** 2015. Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance. *Expert opinion on pharmacotherapy* **16**:2689-2702.
22. **Putcharoen O, Do T, Avihingsanon A, Ruxrungtham K.** 2015. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS. *Drug design, development and therapy* **9**:5763-5769.
23. **Dickinson L, Winston A, Boffito M, Khoo S, Back D, Siccardi M.** 2016. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. *The Journal of antimicrobial chemotherapy* **71**:1041-1045.
24. **Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE.** 2007. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. *Antimicrobial agents and chemotherapy* **51**:2546-2551.
25. **AbbVie Limited.** Norvir 100mg film-coated tablets, Product Information Sheet <https://www.medicines.org.uk/emc/medicine/22952>. Accessed on: 12 August 2016.
26. **Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS.** 2006. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. *Drug metabolism and disposition: the biological fate of chemicals* **34**:1600-1605.
27. **McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ.** 2004. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. *Drug metabolism and disposition: the biological fate of chemicals* **32**:1247-1253.
28. **Chiba M, Ishii Y, Sugiyama Y.** 2009. Prediction of hepatic clearance in human from in vitro data for successful drug development. *The AAPS journal* **11**:262-276.
29. **Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, Guzelian PS.** 1985. Identification of an inducible form of cytochrome P-450 in human liver. *Proceedings of the National Academy of Sciences of the United States of America* **82**:6310-6314.
30. **Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD.** 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. *Drug metabolism and disposition: the biological fate of chemicals* **35**:1853-1859.
31. **Chen J, Raymond K.** 2006. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. *Annals of clinical microbiology and antimicrobials* **5**:3.
32. **Schuetz EG, Schinkel AH, Relling MV, Schuetz JD.** 1996. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. *Proceedings of the National Academy of Sciences of the United States of America* **93**:4001-4005.

33. **Baciewicz AM, Chrisman CR, Finch CK, Self TH.** 2008. Update on rifampin and rifabutin drug interactions. *The American journal of the medical sciences* **335**:126-136.
34. **European Medicines Agency 2013.** Annex I (Darunavir) Janssen-Cilag International NV. Prezista: EU summary of product characteristics.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000707/WC500041756.pdf Accessed on: 12 August 2016.
35. **Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, Bray PG, Back DJ, Khoo SH, Owen A.** 2010. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. *Pharmacogenetics and genomics* **20**:112-120.
36. **Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW.** 2001. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. *Drug metabolism and disposition: the biological fate of chemicals* **29**:754-760.
37. **Choi MK, Jin QR, Choi YL, Ahn SH, Bae MA, Song IS.** 2011. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. *Biopharmaceutics & drug disposition* **32**:175-184.
38. **Annaert P, Ye ZW, Stieger B, Augustijns P.** 2010. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. *Xenobiotica; the fate of foreign compounds in biological systems* **40**:163-176.
39. **Molto J, Xinarianos G, Miranda C, Pushpakom S, Cedeno S, Clotet B, Owen A, Valle M.** 2013. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. *Clinical pharmacokinetics* **52**:543-553.
40. **Colbers A, Greupink R, Litjens C, Burger D, Russel FG.** 2016. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy. *Clinical pharmacokinetics* **55**:381-396.
41. **Marzolini C, Gibbons S, Khoo S, Back D.** 2016. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. *The Journal of antimicrobial chemotherapy*.
42. **Renjifo B, van Wyk J, Salem AH, Bow D, Ng J, Norton M.** 2015. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. *AIDS reviews* **17**:37-46.
43. **Mathias AA, West S, Hui J, Kearney BP.** 2009. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. *Clinical pharmacology and therapeutics* **85**:64-70.
44. **Mathias AA, German P, Murray BP, Wei L, Jain A, West S, Warren D, Hui J, Kearney BP.** 2010. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. *Clinical pharmacology and therapeutics* **87**:322-329.
45. **Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC.** 2010. Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. *ACS medicinal chemistry letters* **1**:209-213.
46. **Gilead.** 2015. Gilead Sciences Ltd, Tybost 150mg film coated tablet, Annex I Summary of Product Characteristics http://ec.europa.eu/health/documents/community-register/2015/20150210131020/anx_131020_en.pdf.
47. **Liu L, Unadkat JD.** 2013. Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs. *Biopharmaceutics & drug disposition* **34**:155-164.
48. **Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H.** 2009. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. *Biological & pharmaceutical bulletin* **32**:1588-1593.

49. **Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A.** 2011. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. *Clinical pharmacology and therapeutics* **89**:234-242.
50. **Boffito M, Miralles D, Hill A.** 2008. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients. *HIV clinical trials* **9**:418-427.
51. **Tashima K, Crofoot G, Tomaka FL, Kakuda TN, Brochot A, Van de Casteele T, Opsomer M, Garner W, Margot N, Custodio JM, Fordyce MW, Szwarcberg J.** 2014. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. *AIDS research and therapy* **11**:39.
52. **Mascolini M.** 2010. 11th International Workshop on Clinical Pharmacology and HIV Therapy, Sorrento.
53. **Ramanathan S, Wang, H., Szwarcberg, J. & Kearney, B.P.** 2012. Safety/Tolerability, Pharmacokinetics, and Boosting of Twice-daily Cobicistat Administered Alone or in Combination with Darunavir or Tipranavir 13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain.
54. **Rostami-Hodjegan A, Tucker GT.** 2007. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. *Nature reviews. Drug discovery* **6**:140-148.
55. **Wienkers LC, Heath TG.** 2005. Predicting in vivo drug interactions from in vitro drug discovery data. *Nature reviews. Drug discovery* **4**:825-833.
56. **Jamei M.** 2016. Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. *Current pharmacology reports* **2**:161-169.
57. **Siccardi M, Rajoli RKR, Curley P, Olagunju A, Moss D, Owen A.** 2013. Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. *Future Virology* **8**:871-890.
58. **Yamashita F, Sasa Y, Yoshida S, Hisaka A, Asai Y, Kitano H, Hashida M, Suzuki H.** 2013. Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data. *PloS one* **8**:e70330.

FIGURES AND FIGURE LEGENDS

FIGURE 1




Figure 1: Effects of rifampicin alone, or in combination with ritonavir, on mean DRV CL_{int,app.} in primary human hepatocytes *in vitro*. Cryopreserved primary human hepatocytes were incubated with rifampicin (RIF; 0.5—20 μM), hatched bars; or with ritonavir (RTV; 0.01–10 μM) and RIF (0.5—20 μM), grey bars; each day for 72 hours. All cells were then incubated with RIF (0.5—20 μM), or RIF (0.5—20 μM) together with RTV (0.01–10 μM) as described above, together with darunavir (DRV; 5 μM), black bar, for 60 minutes. Control cells were treated with DRV (5 μM) alone for 60 minutes. The results shown represent the mean DRV CL_{int,app.} from three biological replicates measured in hepatocytes from three independent donors (Lot HU1399, HU1587 and HU1621). Error bars: SD.

FIGURE 2




Figure 2: Effects of rifampicin alone, or in combination with cobicistat, on mean DRV

CL_{int.app.} in primary human hepatocytes *in vitro*. Cryopreserved primary human hepatocytes

were incubated with rifampicin (RIF; 0.5—20 μM), hatched bars; or with cobicistat (COBI;

0.13—12.76 μM) and RIF (0.5—20 μM), grey bars; each day for 72 hours. All cells were then

incubated with RIF (0.5—20 μM), or RIF (0.5—20 μM) together with cobicistat (COBI; 0.13—


12.76 μM) as described above, together with darunavir (DRV; 5 μM), black bar, for 60 minutes.

Control cells were treated with DRV (5 μM) alone for 60 minutes. The results shown represent

the mean DRV CL_{int.app.} from three biological replicates measured in hepatocytes from three

independent donors (Lot HU1399, HU1574 and HU1587). Error bars: SD.

524 **FIGURE 3**



525

526 **Figure 3: Relative effectiveness of COBI and RTV at lowering RIF-induced DRV $CL_{int.app.}$.**

527 Line graph shows the percentage inhibition of 10 μM rifampicin (RIF)-induced elevations in

528 DRV $CL_{int.app.}$ in cryopreserved primary human hepatocytes following co-incubation with

529 ritonavir (RTV; 0.1—10 μM ; donors HU1399, HU1587 and HU1621), or cobicistat (COBI;

530 0.13—12.76 μM , donors HU1399, HU1574 and HU1587) in combination with RIF (10 μM) for

531 72 hours. Each condition was tested in triplicate in each donor. RTV and COBI concentrations

532 are presented as \log_{10} (μM value-0.001). Error bars: SD.

533

534 **TABLES**535 **TABLE 1**536 **Table 1:** Donor Demographic Information for Cryopreserved Primary Human Hepatocytes Used

Donor	Sex	Race	Age	Medications	Drug Use
HU1399	Female	Caucasian	72	Insulin glargine: 10 units <i>qd</i> ; Metoprolol: 100 mg <i>qd</i> ; Lisinopril hydrochlorothiazide: 20/12.5 mg <i>qd</i> ; Calcium + Vitamin D: 500 mg <i>qd</i> ; Multivitamin: <i>qd</i> ; Aspirin: 81 mg <i>qd</i>	Historic long- term tobacco use
HU1574	Male	Caucasian	70	Atorvastatin: 80 mg <i>qd</i> ; Lisinopril: 5 mg <i>qd</i> .; Aspirin: 81 mg <i>qd</i> ; Tamsulosin: 4 mg <i>qd</i>	None reported
HU1587	Female	Caucasian	43	Vitamin D oral; Multivitamin oral; Calcium + Vitamin D + Vitamin K	None reported
HU1621	Male	Caucasian	66	Pazopanib: 800 mg <i>qd</i>	Rare alcohol use. Historic tobacco use

537